English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThis prestigious award is given to a single candidate annually. It recognizes the contributions of new investigators in building a scientific foundation for oncology nursing practice.
Pozzar was recognized for research aimed at overcoming barriers to delivering high-quality supportive cancer care. Pozzar designed the Collaborative Agenda-Setting Intervention (CASI) for patients with gynecologic cancers, which allows for patient-clinician communication to be optimized as part of routine treatment practice. Additionally, she is currently leading a study to identify optimal strategies by which to engage racially and ethnically diverse patients and clinicians in a digital health tool for remote symptom monitoring.
Pozzar will be recognized during the ONS 48th Annual Congress, April 26-30, 2023, in San Antonio, Texas. As part of the award ceremony, she will give a lecture that highlights her work and current research studies.
Pozzar joined Dana-Farber in 2015 as a PhD student, collaborating with the Cantor Center faculty on several research projects. “From the time I joined Dana-Farber, I have had access to the resources and expertise I’ve needed to conduct rigorous and impactful research,” said Pozzar. “The Cantor Center is unique in that it is one of only a few centers for nursing research embedded within a health care institution. Being a part of the Cantor Center has allowed me to benefit from interdisciplinary collaboration with other Dana-Farber faculty while fostering the growth and visibility of nursing science at our institution.”
The ONS Victoria Mock New Investigator Award is named for Dr. Victoria Mock, who was a nursing pioneer in the 1980s whose work focused on fatigue management interventions. She passed away from cancer a few years ago.
Pozzar is the fourth Dana-Farber Cantor Center nurse scientist to win the award. Robert Knoerl, PhD, RN, was the recipient in 2019, Meghan Underhill-Blazey, PhD, RN, AOCNS was the recipient in 2018 and Mary Cooley, PhD, RN, FAAN was the recipient in 2003.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
###
